# A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

> **NCT04528706** · PHASE2 · UNKNOWN · sponsor: **Minoryx Therapeutics, S.L.** · enrollment: 13 (estimated)

## Conditions studied

- Cerebral Adrenoleukodystrophy

## Interventions

- **DRUG:** MIN-102

## Key facts

- **NCT ID:** NCT04528706
- **Lead sponsor:** Minoryx Therapeutics, S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-13
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2023-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04528706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04528706, "A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04528706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*